Entering text into the input field will update the search result below

ImmunoGen sees 2020 revenue as high as $60M

Jul. 31, 2020 10:01 AM ETImmunoGen, Inc. (IMGN) StockBy: Douglas W. House, SA News Editor
  • ImmunoGen (NASDAQ:IMGN -6.8%) Q2 results:
  • Revenues: $15.0M (-3.2%); non-cash royalty revenue: $14.1M (+35.6%).
  • Net loss: ($24.3M); loss/share: ($0.14).
  • 2020 guidance: Revenues: $60M - 65M; operating expenses: $165M - 170M; cash and equivalents at year-end: $170M - 175M.
  • September: Present mature data from FORWARD II study's platinum-sensitive triplet cohort at ESMO.
  • Q4: Support launch of investigator-sponsored study comparing mirvetuximab plus carboplatin to standard platinum-based chemo in recurrent platinum-sensitive ovarian cancer. Present updated data IMGN632 at ASH. Launch Phase 1 study of IMGC936 in ADAM-9-positive tumors.
  • ImmunoGen EPS beats by $0.03, beats on revenue

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
IMGN--
ImmunoGen, Inc.